biosimilars for ibd: to start, switch, or stay away?
Published 5 years ago • 695 plays • Length 18:23Download video MP4
Download video MP3
Similar videos
-
23:20
biosimilars for ibd: when to start, switch, or stay away?
-
20:47
biosimilars for ibd: start, switch, or stay away?
-
16:48
biosimilars in ibd: where do we stand today?
-
16:44
the current landscape of biosimilars in ibd
-
16:22
incorporating ibd biosimilars into practice: patient care and education
-
4:04
biosimilars and inflammatory bowel disease
-
10:00
ibd clinical case: the process of switching from a reference biologic to a biosimilar
-
39:51
why ibd patients should know about biosimilars
-
11:03
biosimilars in the us and beyond
-
32:29
keynote speaker: understanding the monitoring and safety of ibd medications and biologics
-
1:22:22
making the switch from biologics to biosimilars in ibd: knowledge over skepticism
-
20:40
patient care in ibd: incorporating biosimilars into clinical practice
-
11:40
debate: biosimilar therapies - caution, more studies are needed
-
5:34
ibd: switching from a biologic to a biosimilar
-
23:44
mechanisms of disease: biologic pipeline for ibd
-
21:14
when and how to use immunomodulators and biologics in ibd
-
13:19
what are biosimilar therapies and why should we care?
-
20:34
key insights: biosimilars and novel targets in ibd
-
1:47
understanding biosimilars - for ibd patients